Navigation Links
DATATRAK International Management To Host Conference Call on November 8, 2007 To Discuss Third Quarter and Nine Month Operating Results for 2007
Date:11/1/2007

logies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 17 drugs and devices that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward- looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's de
'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. International community warns India on HIV situation
2. Key step forward on International Health Rules
3. ICMR along with other International Research organisation with drug development for Neglected Diseases
4. International Osteoporosis Research Centre To Be Started In India.
5. Indian hospitals require International Accreditation
6. International Conference On Malaria - Laveran To Genomics
7. Delhi To Host International Women’s Congress From Nov 2
8. International conference on Ayurveda to be held on Kerala
9. International Teleradiology: The Future Of Radiologic Diagnosis
10. International Rating System To Be Introduced For Hospitals In India
11. John Mendelsohn M.D, chosen for an International Award

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ting firm LocumTenens.com, a leading provider of t...e its agreement with VHA Inc., a national healthca... assignments. , Alpharett...uiting firm LocumTenens.com , a leading provider...nounce its agreement with VHA Inc., a national hea...
(Date:11/24/2009)...use of inflammatory bowel disease is largely unkno... 2009 Advances in Inflammatory Bowel Diseases, the...inical & Research Conference, December 3-6 in ...mutation for Crohn’s disease. , ...9 -- The molecular cause of inflammatory bowel dis...
(Date:11/24/2009)...SNewswire/--GovernorEdwardG.Rendelltodayannouncedt...ccinatedduringtheweekendatpublichealthclinicsheldb..., "Withthefederalgovernmentunabletoprovideaccur...ofH1N1vaccine,distributionhasbeenchallenging,"said...ccinedistributionprocessinPennsylvania.Holdingpubl...
(Date:11/24/2009)...e/--AgitoNetworks,Inc.,thecompanydeliveringinnovat...titwashonoredintheEverythingChannelTechInnovatorAw....0.EverythingChannel,sTechInnovatorAwardscelebrate...tdriveadvancesthroughoutthetechnologychannel. ,...pplicationsforthe2009EverythingChannelTechInnovato...
(Date:11/24/2009)...wire/--Nextmonth,UnitedHealthcarewilloffertwofreeM...ricanseniorsunderstandthebasicsofMedicare.Followin...174;Goldclass,aLatin-infusedfitnessprogramthatblen.... ,, UnitedHealthcarewilloffertheseseminarsinSp...arningabouttheirhealthcareoptions. Thereareapprox...
Breaking Medicine News(10 mins):Health News:VHA Names LocumTenens.com as Preferred Physician Staffing Vendor 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2Health News:Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 2Health News:Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 3Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2
...leep Loss Costs Economy up to $15 Billion Each Yea...S, March 30 Now more than ever, Americans need th...of the first things people scrimp on when time is ...p in America poll by the National Sleep Foundation...
...nhancements maximize and automate physician practi...ain financial edge during economic downturn , , ...ding developer of healthcare software solutions fo...ca,s award-winning Electronic Health Record (EHR) ...
... , , , - Lorcaserin Very Well Tolerated Througho... for Today at 8:30 a.m. EDT , , SAN DIEGO, March...ARNA ) announced today positive top-line results f...ficacy of lorcaserin for weight management. Statis...
...INCINNATI, March 30 LCA-Vision Inc. (Nasdaq: LC...n services under the Lasik Plus (R) brand, today a...g with the Securities and Exchange Commission, the... Additionally, the Joffe Group stated that it has...
...ompany also Introduces Everest Award for Hospitals... , ANN ARBOR, Mich., March 30 The Healthcare bus... study identifying the 100 top U.S. hospitals base...Hospitals National Balanced Scorecard that evaluat...
...orld-renowned neurosurgeon for over 40 years, Dr. ...body and spirit are essential for optimum health. ...Ft. Wayne, Indiana, Rudy Kachmann, M.D., creator o...s. Now, having retained award-winning TransMedia G...
Other Medicine News:Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 2Health News:iMedica Corporation Announces the Release of Patient Relationship Manager 2009 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 2Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 4Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 5Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 6Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 7Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 8Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 9Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 10Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 11Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 4Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 5Health News:Dr. Rudy Kachmann, Neurosurgeon, Author, Lecturer & Founder of Kachmann Mind Body Institute Selects TransMedia Group as Agency of Record 2
(Date:11/24/2009)...ov.24/PRNewswire/--ZargisMedicalCorp.,asubsidiaryo...sCorporateResearch(NYSE: SI ),todayannouncedthatit...2009episodeofCBS, TheEarlyShow duringasegmentinwhi...eviewedfivewinningproductsfromthepublication,s2009...dely-viewedtelevisionmorningnewstalkshowbroadcastb...
(Date:11/24/2009)...PRNewswire/--AmbitBiosciencesCorporationannouncedt...AC220,anovelsecondgenerationFLT3inhibitor,inAMLatt...)tobeheldinNewOrleans,LA,December5-8,2009.Anoralpr...lPhaseImonotherapysafetystudyinadultswithacutemyel...bepresentedevaluatingtheeffectofAC220monotherapyan...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--EchoTherapeutics,Inc....e-freeSymphony(TM)tCGMSystemasanon-invasive,wirele...temanditsPrelude(TM)SkinPrepSystemfortransdermaldr...ChairmanandChiefExecutiveOfficer,willpresentatthe1...nce,sponsoredbytheNewYorkSocietyofSecuritiesAnalys...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 1Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 1YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 4Beckman Coulter Announces Third Quarter 2009 Results 5858 1Beckman Coulter Announces Third Quarter 2009 Results 5858 2Beckman Coulter Announces Third Quarter 2009 Results 5858 3Beckman Coulter Announces Third Quarter 2009 Results 5858 4Beckman Coulter Announces Third Quarter 2009 Results 5858 5Beckman Coulter Announces Third Quarter 2009 Results 5858 6Beckman Coulter Announces Third Quarter 2009 Results 5858 7Beckman Coulter Announces Third Quarter 2009 Results 5858 8Beckman Coulter Announces Third Quarter 2009 Results 5858 9Beckman Coulter Announces Third Quarter 2009 Results 5858 10Beckman Coulter Announces Third Quarter 2009 Results 5858 11Beckman Coulter Announces Third Quarter 2009 Results 5858 12Beckman Coulter Announces Third Quarter 2009 Results 5858 13Beckman Coulter Announces Third Quarter 2009 Results 5858 14Beckman Coulter Announces Third Quarter 2009 Results 5858 15Beckman Coulter Announces Third Quarter 2009 Results 5858 16Beckman Coulter Announces Third Quarter 2009 Results 5858 17Beckman Coulter Announces Third Quarter 2009 Results 5858 18Beckman Coulter Announces Third Quarter 2009 Results 5858 19Beckman Coulter Announces Third Quarter 2009 Results 5858 20Beckman Coulter Announces Third Quarter 2009 Results 5858 21Beckman Coulter Announces Third Quarter 2009 Results 5858 22Beckman Coulter Announces Third Quarter 2009 Results 5858 23Beckman Coulter Announces Third Quarter 2009 Results 5858 24Beckman Coulter Announces Third Quarter 2009 Results 5858 25Beckman Coulter Announces Third Quarter 2009 Results 5858 26Beckman Coulter Announces Third Quarter 2009 Results 5858 27Beckman Coulter Announces Third Quarter 2009 Results 5858 28Beckman Coulter Announces Third Quarter 2009 Results 5858 29Beckman Coulter Announces Third Quarter 2009 Results 5858 30Beckman Coulter Announces Third Quarter 2009 Results 5858 31Beckman Coulter Announces Third Quarter 2009 Results 5858 32Beckman Coulter Announces Third Quarter 2009 Results 5858 33Beckman Coulter Announces Third Quarter 2009 Results 5858 34Beckman Coulter Announces Third Quarter 2009 Results 5858 35
...oBio Corporation is,presenting safety and efficacy...alis (cold sores) and onychomycosis (toe nail fung...of Dermatology (AAD), being held February,1-5, 200...cate that the company,s topical lotions,composed o...and antifungal,effects without safety concerns or ...
...ts targeted as part of innovative,Therapeutics Dev...f its ongoing,efforts to do whatever it takes to s...ure for Parkinson,s disease, The Michael J. Fox,Fo...o $3 million in total,funding to four industry tea...ser to the clinic. The awards were granted under M...
Other Medicine Technology:NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008 2NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008 3Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
...eoGen surgically implanted bone growth stimulator ... when surgery is already planned or when patient c...s totally surgically implanted, patients are assur...on site 24 hours a day for up to 6 months. , ,...
BIG ADVANTAGE Cannulated Titanium Interference Screws
...rew ACL Interference Screw is indicated for graft ...and PCL reconstructions with bone-patellar tendon-... SmartScrew ACL provides easy and atraumatic inser... type. The unique Self-Reinforced 96L/4D copolymer...
ADVANTAGE Titanium Cannulated Interference Screws
Medicine Products: